EA201270662A1 - Связывающие элементы для человеческого цитамегаловируса - Google Patents

Связывающие элементы для человеческого цитамегаловируса

Info

Publication number
EA201270662A1
EA201270662A1 EA201270662A EA201270662A EA201270662A1 EA 201270662 A1 EA201270662 A1 EA 201270662A1 EA 201270662 A EA201270662 A EA 201270662A EA 201270662 A EA201270662 A EA 201270662A EA 201270662 A1 EA201270662 A1 EA 201270662A1
Authority
EA
Eurasian Patent Office
Prior art keywords
binding elements
human
cytamegalovirus
hmvc
binding
Prior art date
Application number
EA201270662A
Other languages
English (en)
Inventor
Ульф Гравундер
Михель Мах
Луис Мартин-Паррас
Соня Пёцш
Надя Шпиндлер
Хейнрих Штихт
Анна-Катарина Вигерс
Томас Винклер
Original Assignee
4-Антибоди Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4-Антибоди Аг filed Critical 4-Антибоди Аг
Publication of EA201270662A1 publication Critical patent/EA201270662A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/088—Varicella-zoster virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к связывающим элементам, главным образом молекулам антитела, нейтрализующим биологические эффекты человеческого цитомегаловируса (чЦМВ). Связывающие элементы применяются для лечения и профилактики чЦМВ-инфекции.
EA201270662A 2009-12-23 2010-12-22 Связывающие элементы для человеческого цитамегаловируса EA201270662A1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28983509P 2009-12-23 2009-12-23
EP09015951 2009-12-23
US32005710P 2010-04-01 2010-04-01
EP10003669 2010-04-01
PCT/EP2010/070568 WO2011076883A1 (en) 2009-12-23 2010-12-22 Binding members for human cytomegalovirus

Publications (1)

Publication Number Publication Date
EA201270662A1 true EA201270662A1 (ru) 2013-01-30

Family

ID=44246877

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270662A EA201270662A1 (ru) 2009-12-23 2010-12-22 Связывающие элементы для человеческого цитамегаловируса

Country Status (17)

Country Link
US (1) US9346874B2 (ru)
EP (1) EP2516463B1 (ru)
JP (1) JP5833565B2 (ru)
KR (1) KR20120105543A (ru)
CN (1) CN102892782B (ru)
AU (1) AU2010334809C1 (ru)
BR (1) BR112012015523A2 (ru)
CA (1) CA2785587A1 (ru)
CO (1) CO6640284A2 (ru)
EA (1) EA201270662A1 (ru)
HK (1) HK1181398A1 (ru)
IL (1) IL220617A0 (ru)
MX (1) MX2012007489A (ru)
NZ (1) NZ600974A (ru)
SG (1) SG181901A1 (ru)
WO (1) WO2011076883A1 (ru)
ZA (1) ZA201204513B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE036122T2 (hu) 2010-05-14 2018-06-28 Univ Oregon Health & Science Rekombináns HCMV és RhCMV vektorok és alkalmazásaik
PT2691530T (pt) 2011-06-10 2018-05-10 Univ Oregon Health & Science Glicoproteínas e vectores recombinantes cmv
EP2831119A1 (en) * 2012-03-28 2015-02-04 F. Hoffmann-La Roche AG Anti-hcmv idiotypic antibodies and uses thereof
US20150110794A1 (en) * 2012-04-30 2015-04-23 Cell Signaling Technology, Inc. Anti-Human Cytomegalovirus Antibodies And Use Thereof
ES2696703T3 (es) * 2013-03-05 2019-01-17 Univ Oregon Health & Science Vectores de citomegalovirus que permiten el control del direccionamiento de los linfocitos T
US20150152166A1 (en) * 2013-04-19 2015-06-04 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of cytomegalovirus
CA2912913A1 (en) * 2013-06-10 2014-12-18 Merck Sharp & Dohme Corp. Cmv neutralizing antigen binding proteins
KR101996427B1 (ko) 2014-07-16 2019-07-04 오레곤 헬스 앤드 사이언스 유니버시티 외인성 항원을 포함하는 인간 시토메갈로바이러스
EA201791806A1 (ru) 2015-02-10 2017-12-29 Орегон Хелс Энд Сайенс Юниверсити Способы и композиции, полезные при генерировании неканонических cd8+ т-клеточных ответов
CN108474003A (zh) 2015-11-20 2018-08-31 俄勒冈健康与科学大学 包含微小rna识别元件的cmv载体
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
UA126860C2 (uk) 2016-10-18 2023-02-15 Орегон Хелс Енд Сайєнс Юніверсіті Цитомегаловірусні вектори, що вибирають t-клітини, обмежені по молекулах головного комплексу гістосумісності e
US20210396761A1 (en) * 2018-07-20 2021-12-23 Aicuris Gmbh & Co. Kg Methods for screening and identifying agents that inhibit or modulate the nuclear egress complex of herpesviruses
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN112898414B (zh) * 2019-12-04 2024-05-10 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide
GB202020135D0 (en) * 2020-12-18 2021-02-03 Ucl Business Ltd Immunogenic peptide

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
FR2543570B1 (fr) 1983-03-31 1985-08-09 Pasteur Institut Anticorps monoclonaux anticytomegalovirus humains, hybridomes secreteurs de ces anticorps et polypeptides porteurs d'un determinant antigenique sequentiel de cytomegalovirus humains
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8404368D0 (en) 1984-02-20 1984-03-28 Cogent Ltd Monoclonal antibodies to human cytomegalovirus
US4618578A (en) 1984-07-17 1986-10-21 Chiron Corporation Expression of glycoprotein D of herpes simplex virus
US5244792A (en) 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
US5171568A (en) 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
FR2563630B1 (fr) 1984-04-27 1988-02-19 Pasteur Institut Anticorps monoclonaux anticytomegalovirus et procedes pour le diagnostic in vitro des infections par les cytomegalovirus humains et d'une proteine-kinase inductible par les cytomegalovirus et susceptible d'etre reconnue par les susdits anticorps monoclonaux
US5612041A (en) 1984-07-17 1997-03-18 Chiron Corporation Recombinant herpes simplex gD vaccine
US4743562A (en) 1984-08-21 1988-05-10 The Board Of Trustees Of The Leland Stanford Junior University Purified human cytomegalovirus protein
US5194256A (en) 1984-08-21 1993-03-16 The Board Of Trustees Of The Leland Sanford Junior University Purified human cytomegalovirus protein
DE3581400D1 (de) 1984-09-28 1991-02-21 Teijin Ltd Maus/mensch-hybridoma mit erzeugung von antiviralen menschlichen antikoerpern, deren herstellung und antivirale menschliche monoklonale antikoerper.
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
WO1987003602A1 (en) 1985-12-06 1987-06-18 Teijin Limited Anticytomegaloviral human monoclonal antibody and process for its preparation
US6162620A (en) 1986-03-07 2000-12-19 Cogent Limited Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ES2044881T3 (es) 1986-06-12 1994-01-16 Behringwerke Ag Procedimiento para la preparacion de una fosfoproteina estructural (pp 150) del citomegalovirus humano.
US5124440A (en) 1986-11-24 1992-06-23 The Childrens Hospital, Inc. Antibody and T cell recognition sites on glycoproteins comprising the GCI complex of human cytomegalovirus
US5248768A (en) 1986-11-24 1993-09-28 The Children's Hospital, Incorporated Immunogenic glycoproteins of human cytomegalovirus
US5153311A (en) 1986-11-24 1992-10-06 The Children's Hospital, Incorporated Immunogenic glycoproteins of human cytomegalovirus gCII
US5126130A (en) 1986-11-24 1992-06-30 The Childrens Hospital Incorporated Monoclonal antibodies reactive with specific antigenic sites on human cytomegalovirus glycoprotein a
LU86752A1 (fr) 1987-01-30 1988-08-23 Univ Bruxelles Procede de production d'anticorps monoclonaux humains(igg)anticytomegalovirus et anticorps monoclonaux ainsi obtenus
GB8729251D0 (en) 1987-12-15 1988-01-27 Cogent Ltd Human cytomegalovirus protein
AU641121B2 (en) 1988-01-29 1993-09-16 Chiron Corporation Recombinant CMV neutralizing proteins
US5547834A (en) 1988-01-29 1996-08-20 Chiron Corporation Recombinant CMV neutralizing proteins
US6733989B1 (en) 1988-02-24 2004-05-11 Dade Behring Marburg Gmbh Structural phosphoprotein (pp28) of human cytomegalovirus (HCMV), the preparation and use thereof
AU3550489A (en) 1988-05-09 1989-11-29 Children's Hospital Incorporated, The Vectors encoding hcmv glycoprotein and expression products
US5185243A (en) 1988-08-25 1993-02-09 Syntex (U.S.A.) Inc. Method for detection of specific nucleic acid sequences
WO1990006771A1 (en) 1988-12-12 1990-06-28 The Children's Hospital, Incorporated Proteolytic fragments obtained from human cytomegalovirus glycoprotein complex i
US5180813A (en) 1989-03-24 1993-01-19 University Of Iowa Research Foundation Early envelope glycoprotein of human cytomegalovirus (hmcv) and monoclonal antibodies to the glycoproteins
WO1991002004A1 (en) 1989-08-07 1991-02-21 Children's Biomedical Research Center IMMUNOGENIC GLYCOPROTEINS OF HUMAN CYTOMEGALOVIRUS gCII
WO1991004277A1 (en) 1989-09-14 1991-04-04 Children's Biomedical Research Institute Monoclonal antibodies specific to cytomegalovirus glycoprotein
WO1991005876A1 (en) 1989-10-20 1991-05-02 Children's Biomedical Research Institute Human cytomegalovirus-specific monoclonal antibody cocktail
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9008223D0 (en) 1990-04-11 1990-06-13 Royal Free Hosp School Med Improvements relating to the detection of viruses
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP2535455B2 (ja) 1991-02-07 1996-09-18 帝人株式会社 サイトメガロウイルスに対するヒト・モノクロ―ナル抗体を産生するハイブリド―マ
JPH053794A (ja) 1991-06-26 1993-01-14 Green Cross Corp:The 抗サイトメガロウイルスヒトモノクローナル抗体およびその産生細胞
US5744298A (en) 1991-08-29 1998-04-28 Behringwerke Aktiengesellschaft DNA sequences which encode immunoreactive HCMV-specific peptides
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
SE9201281L (sv) 1992-04-23 1993-10-24 Bioinvent Int Ab Nya humana monoklonala antikroppar och förfarande för framställning därav
JPH05260961A (ja) 1992-05-21 1993-10-12 Teijin Ltd サイトメガロウイルスに対するヒト・モノクローナル抗体を産生するハイブリドーマ
GB9221654D0 (en) 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
JPH06157349A (ja) 1992-11-13 1994-06-03 Teijin Ltd サイトメガロウイルス感染症治療剤
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5750106A (en) 1993-01-28 1998-05-12 Novartis Ag Human monoclonal antibodies to cytomegalovirus
WO1994025490A1 (en) 1993-04-30 1994-11-10 The Scripps Research Institute Human monoclonal antibodies to human cytomegalovirus, and methods therefor
JP2538536B2 (ja) 1994-07-06 1996-09-25 帝人株式会社 サイトメガロウイルスに対するヒト・モノクロ―ナル抗体を産生するハイブリド―マ
JP2538537B2 (ja) 1994-07-06 1996-09-25 帝人株式会社 サイトメガロウイルスに対するヒト・モノクロ―ナル抗体
JPH0859509A (ja) 1994-08-16 1996-03-05 Teijin Ltd サイトメガロウイルス抗原血症治療剤およびサイトメガロウイルス感染症治療剤
JPH0859508A (ja) 1994-08-16 1996-03-05 Teijin Ltd サイトメガロウイルス網膜炎予防または治療剤
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5783383A (en) 1995-05-23 1998-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of detecting cytomegalovirus (CMV)
US20020102562A1 (en) 1995-05-24 2002-08-01 Pasteur Merieux Serums Et Vaccines S.A. Recombinant CMV neutralizing proteins
US5800981A (en) 1996-02-22 1998-09-01 University Of Limburg Human cytomegalovirus antigen and its use
US5814468A (en) 1996-03-27 1998-09-29 Coulter International Corp. Methods of enumerating receptor molecules for specific binding partners on formed bodies and in solution
JP2000516617A (ja) 1996-08-14 2000-12-12 ザ・ウイスター・インステイテユート・オブ・アナトミー・アンド・バイオロジー アテローム性動脈硬化病変の出現を予防するか又は遅らせるための方法及び組成物
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
DE19756214C1 (de) 1997-12-17 1999-02-25 Biotest Ag Polypeptide mit Aminosäuresequenzen aus dem N-terminalen Bereich von gp116 und deren Verwendung bei der Diagnostik, Prophylaxe und Therapie
WO1999054342A1 (en) 1998-04-20 1999-10-28 Pablo Umana Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
DK1137941T4 (da) 1998-12-10 2014-01-06 Brystol Myers Squibb Company Protein-scaffolds til antistof-mimetika og andre bindingsproteiner
US6569616B1 (en) 1999-07-29 2003-05-27 Wisconsin Alumni Research Foundation Human cytomegalovirus glycoprotein O as a new drug target and subunit vaccine candidate
AU2001288682A1 (en) 2000-08-30 2002-03-13 Chemocentryx, Inc. Inhibition of cmv infection and dissemination
ATE488583T1 (de) 2001-02-21 2010-12-15 Wistar Inst Rekombinant vektor, der ein infektiöses humanes cytomegalovirus genom mit konserviertem wildtyp- charakteristika klinisher isolate enthält
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
CN100423777C (zh) 2001-10-25 2008-10-08 杰南技术公司 糖蛋白组合物
JP4238138B2 (ja) 2001-12-22 2009-03-11 ４−アンチボディ アーゲー 遺伝的に修飾された脊椎動物前駆体リンパ球の生成方法及び異種結合タンパク質の産生を目的としたその使用。
GB2398783A (en) 2003-02-26 2004-09-01 Antonio Lanzavecchia A method for producing immortalised human B memory lymphocytes
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
US20040228842A1 (en) 2003-02-27 2004-11-18 Shan Lu Compositions and methods for cytomegalovirus treatment
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US7976845B2 (en) 2004-11-29 2011-07-12 The Council Of The Queensland Institute Of Medical Research Human cytomegalovirus immunotherapy
ES2367322T3 (es) 2005-12-16 2011-11-02 Ribovax Biotechnologies Sa Métodos para obtener células inmortalizadas que secretan anticuerpos.
JPWO2007094423A1 (ja) 2006-02-15 2009-07-09 株式会社イーベック ヒトサイトメガロウイルスに結合するヒトのモノクローナル抗体並びにその抗原結合部分
US7704510B2 (en) 2006-06-07 2010-04-27 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
GB0612944D0 (en) * 2006-06-29 2006-08-09 Bhr Group Ltd Water jet cutting apparatus
AU2007331463B2 (en) 2006-12-15 2014-03-27 Ribovax Biotechnologies Sa Antibodies against human cytomegalovirus (hCMV)
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
AU2008213356A1 (en) 2007-02-07 2008-08-14 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Recombinant antigens of human cytomegalovirus (HCMV)
US20100158927A1 (en) 2007-03-29 2010-06-24 Technion Research & Development Foundation Ltd. Antibodies, methods and kits for diagnosing and treating melanoma
WO2008120203A2 (en) 2007-03-29 2008-10-09 Technion Research & Development Foundation Ltd. Antibodies and their uses for diagnosis and treatment of cytomegalovirus infection and associated diseases
EP2173771A1 (en) 2007-07-04 2010-04-14 Ribovax Biotechnologies SA Antibodies against human cytomegalovirus (hcmv)
EP2190876A1 (en) 2007-08-22 2010-06-02 Ribovax Biotechnologies SA Antibodies against human cytomegalovirus (hcmv)
US7763261B2 (en) 2007-12-19 2010-07-27 Dcb-Usa Llc Anti-human cytomegalovirus antibodies
EP2257571B1 (en) 2008-03-10 2015-03-04 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
CN102203133B (zh) 2008-07-16 2015-01-07 生物医学研究学会 人巨细胞病毒中和抗体及其应用
KR20150002895A (ko) 2008-07-16 2015-01-07 인스티튜트 포 리서치 인 바이오메드슨 인간 사이토메갈바이러스 중화 항체 및 이의 용도
SI2420572T1 (sl) 2009-04-01 2015-10-30 Evec Incorporated Monoklonsko protitelo, ki je sposobno vezave na specifični diskontinuirani epitop, ki se pojavi pri regiji ad1 glikoproteina gb človeškega citomegalovirusa, in njegov antigen-vezavni fragment
CA2839420C (en) 2010-06-16 2023-06-13 Lawrence M. Kauvar High affinity human antibodies to human cytomegalovirus (cmv) gb protein

Also Published As

Publication number Publication date
AU2010334809B2 (en) 2014-10-23
IL220617A0 (en) 2012-08-30
US20130089559A1 (en) 2013-04-11
NZ600974A (en) 2014-08-29
AU2010334809C1 (en) 2015-02-26
EP2516463B1 (en) 2016-06-15
WO2011076883A1 (en) 2011-06-30
US9346874B2 (en) 2016-05-24
EP2516463A1 (en) 2012-10-31
BR112012015523A2 (pt) 2017-04-18
ZA201204513B (en) 2013-02-27
CA2785587A1 (en) 2011-06-30
JP2013515469A (ja) 2013-05-09
CN102892782A (zh) 2013-01-23
HK1181398A1 (en) 2013-11-08
SG181901A1 (en) 2012-08-30
MX2012007489A (es) 2012-11-29
KR20120105543A (ko) 2012-09-25
CN102892782B (zh) 2015-01-14
CO6640284A2 (es) 2013-03-22
JP5833565B2 (ja) 2015-12-16
AU2010334809A1 (en) 2012-07-26

Similar Documents

Publication Publication Date Title
EA201270662A1 (ru) Связывающие элементы для человеческого цитамегаловируса
EA201171237A1 (ru) Антитела к dkk-1
EA201391457A1 (ru) Белки, связывающиеся с bcma (cd269/tnfrsf17)
EA201792465A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201270100A1 (ru) Пиримидиноны в качестве ингибиторов pi3k
EA201200977A1 (ru) Лечение синдрома ли и ли-подобного синдрома токотриенолхинонами
EA201401107A1 (ru) Специфические антагонисты рецептора fgf-r4
EA201491412A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201201000A1 (ru) Способы лечения колоректального рака
EA200971077A1 (ru) Гетероциклические модуляторы киназы
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
AU2012249274A8 (en) Neutralizing antibodies to Nipah and Hendra virus
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
CO6640289A2 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
EA201100505A1 (ru) Органические соединения для применения для лечения бактериальных инфекций
EA201890754A1 (ru) Соединения и способы их применения
EA201101521A1 (ru) Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
MX2014009289A (es) Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
EA201590247A1 (ru) Антитела к siglec-15
EA201270769A1 (ru) Антитела к cgrp
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
BR112013020259A2 (pt) tratamento de osteoartrite e dores
BR112013005116A2 (pt) moduladores e métodos de uso